What is Qualigen?
Qualigen operates at the intersection of advanced biotechnology and therapeutic development, leveraging its proprietary nanoparticle coating technology. This core technology, which has a proven track record in diagnostics through its FDA-approved FastPack® System, is now being applied to a robust pipeline of cancer treatments. Key candidates include ALAN (AS1411-GNP), a DNA-coated gold nanoparticle drug targeting various cancers with potential for minimal side effects; RAS-F3, a small molecule inhibitor designed to block RAS oncogene mutations critical in pancreatic, colorectal, and lung cancers; and STARS, a DNA/RNA-based device for removing targeted tumor-produced and viral compounds from blood. The company's operations are based in Carlsbad, California, with an FDA and ISO Certified facility, and its FastPack® product line is distributed globally via its commercial partner, Sekisui Diagnostics, LLC.
How much funding has Qualigen raised?
Qualigen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Qualigen?
With its substantial capital infusion and late-stage funding context, Qualigen is strategically positioned for significant growth and market penetration. The recent strategic investment signals strong investor confidence in the company's therapeutic candidates and its underlying nanoparticle technology. Future endeavors will likely focus on advancing ALAN, RAS-F3, and STARS through clinical trials, expanding manufacturing capabilities, and broadening commercial reach. The company's established presence in diagnostics, coupled with its innovative approach to oncology and infectious disease treatment, suggests a trajectory aimed at addressing unmet medical needs and capturing a substantial share of the biopharmaceutical market.
See full Qualigen company page
